The present invention relates in part to the discovery that benzodiazepines can be used to reactivate latent HIV-1 virus that is integrated into human genome. In other embodiments, the benzodiazepine is used in combination with a histone deacetylase inhibitor (HDACi), such as but not limited to SAHA (also known as N-hydroxy-N-phenyl-octanediamide, Suberoylanilide hydroxamic acid, Vorinostat). In yet other embodiments, the combination of benzodiazepine and the HDACi synergistically reactivates latent HIV-1 virus that is integrated into human genome, with minimal or no significant toxicity associated with the dose of either agent.

The present invention relates to a compound for use in a method of treating a pathological condition selected from polycystic kidney disease, polycystic liver disease, and a combination thereof. The present invention further relates to a composition for use in a method of treating a pathological condition selected from polycystic kidney disease, polycystic liver disease, and a combination thereof.

The present invention relates to a compound for use in a method of treating a pathological condition selected from polycystic kidney disease, polycystic liver disease, and a combination thereof. The present invention further relates to a composition for use in a method of treating a pathological condition selected from polycystic kidney disease, polycystic liver disease, and a combination thereof.

Provided herein are compounds, derivatives thereof, composition comprising one or more of said compounds and derivatives prevention and/or treatment of microbial infections and/or related diseases or conditions. The present compounds and/or derivatives thereof can be represented by Formula (I):

##STR00001##

In one embodiment, said microbial infections are bacterial infections. More specifically, said bacterial infections are staphylococcal infections.

Provided herein are compounds, derivatives thereof, composition comprising one or more of said compounds and derivatives prevention and/or treatment of microbial infections and/or related diseases or conditions. The present compounds and/or derivatives thereof can be represented by Formula (I):

##STR00001##

In one embodiment, said microbial infections are bacterial infections. More specifically, said bacterial infections are staphylococcal infections.

Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.

Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

Solid-forming local anesthetic formulations for pain control can include a lidocaine base and tetracaine base, polyvinyl alcohol, water, and an emulsifier. The formulation can be prepared to be in a semi-solid state prior to application to a skin surface, can form a soft solidified layer after application, and can provide pain relief when applied to a skin surface proximate a pain site.